beat · 10 stories
Northwest Biotherapeutics filed DCVax-L, a glioblastoma immunotherapy, with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in late 2023 under a 150-day expedited review. Six times that window has now closed in silence.
The standard industrial method for making custom DNA relies on hazardous organic solvents. A Harvard team has replaced that chemistry with a water-based enzymatic reaction wired directly to a silicon chip.
A Boston Children's and Dana-Farber team shows a small genetic edit to the antibody-binding spot on donor blood-forming stem cells lets an antibody clear the patient's own without chemo or radiation.
Mouse and isolated human cell data show dendritic cells use creatine to prime T cells, the metabolic step the same lab first mapped in T cells.
AstraZeneca's $2.1B Sino Biopharm licensing deal targets a dual-formulation version of the inhaled COPD drug class that Merck's Ohtuvayre currently owns as a single-format product.
Pediatricians who prescribe continuous glucose monitors to high-risk kids and those who fear eating disorders are split on whether healthy children should wear one.
A near-bankrupt Minneapolis biotech is staking its survival on a re-engineered version of a human vasodilator protein (kallikrein-1, or KLK1) for acute ischemic stroke — and the ReMEDy2 Phase II/III trial readout before year-end will test whether
Atacicept is a once-weekly injection that blocks BAFF and APRIL, two immune signals driving IgA nephropathy, a rare autoimmune kidney disease; full approval now hinges on whether it slows kidney decline by Q3 2026.
Congress has put Pfizer, Merck, Bristol Myers Squibb and AbbVie on the spot over China clinical trial sites in Xinjiang, including ones tied to the People's Liberation Army. Investors are split.
Vivani's NPM-139, a miniature under-the-skin device designed to release semaglutide for roughly six months, enters phase 1 in coming weeks, with Novo choosing not to lock up the platform.